公开(公告)号：US20220380425A1

公开(公告)日：2022-12-01

申请号：US17624114

申请日：2020-07-04

申请人： CADILA HEALTHCARE LIMITED

发明人： Mukul JAIN ,  Suresh GIRI ,  Rajesh BAHEKAR ,  Rajendra CHOPADE ,  Debdutta BANDYOPADHYAY

IPC分类号： C07K14/515 ,  A61P1/16 ,  A61K39/00

摘要： The present invention relates to a vaccine capable to induce the formation of antibodies directed to angiopoietin-like 3 in vivo. More specifically, the present invention relates to a use of a vaccines which are able to influence the angiopoietin-like 3 mediated immune response for the treatment of liver diseases such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease and hyperlipidaemia, hypercholesterolemia, or atherosclerosis including the complications lead to the cardiovascular diseases (CVD) which causes morbidity and mortality.

公开(公告)号：US20220175721A1

公开(公告)日：2022-06-09

申请号：US17430381

申请日：2020-02-12

申请人： Cadila Healthcare Limited

发明人： Mukul Jain ,  Deven V. Parmar ,  Amit Joharapurkar

IPC分类号： A61K31/40

摘要： Present invention provides the method of treating polycystic ovarian syndrome using compound of formula (I) or pharmaceutically acceptable salt thereof, preferably it provides method of treating polycystic ovarian syndrome in the patient diagnosed with NAFLD. Invention also provides a pharmaceutical composition comprising compound of formula (I) for treatment of polycystic ovarian syndrome, wherein compound of formula (I) is

公开(公告)号：US20220023262A1

公开(公告)日：2022-01-27

申请号：US17383930

申请日：2021-07-23

申请人： CADILA HEALTHCARE LIMITED

发明人： Kumar Kamlesh SINGH ,  Sanjay Jagdish DESAI ,  Piyush Rajendra SHARMA ,  Daya Ram PAL ,  Sanjeev Kumar TRIPATHI ,  Mayur Ramnikbhai PATEL

IPC分类号： A61K31/4025 ,  A61K31/336

摘要： The present invention relates to a composition comprising high purity pyrrole derivative and method for preparation thereof. The present invention particularly relates to compositions comprising Saroglitazar magnesium having purity of 99.0% or more, and one or more of an aldehyde compound of Formula (II), diketo oxirane compound of Formula (III), hydroxy methyl compound of Formula (IV) or dimer compound of Formula (V), relative to saroglitazar magnesium, each present in an amount of about 0.15% or less, respectively, by weight, when measured by area percentage of HPLC.

公开(公告)号：US11110073B2

公开(公告)日：2021-09-07

申请号：US15933937

申请日：2018-03-23

申请人： CADILA HEALTHCARE LIMITED

发明人： Sushilkumar Dhanaji Patil ,  Nirav Ishwarlal Khatri ,  Alex Kochukunju George ,  Sushrut Krishnaji Kulkarni

IPC分类号： A61K31/196 ,  A61K9/00 ,  A61K45/06 ,  A61K47/32 ,  A61K9/08

摘要： The present invention relates to a stable, aqueous, injectable solution comprising diclofenac and polyvinylpyrrolidone. The present invention also relates to processes for preparing the injectable solution.

公开(公告)号：US10925871B2

公开(公告)日：2021-02-23

申请号：US15121514

申请日：2015-02-25

申请人： CADILA HEALTHCARE LIMITED

发明人： Brij Khera ,  Muthaiyyan Essakimuthu Kannan ,  Jitendra Rameshchandra Patel ,  Saurin Mukundbhai Amin

IPC分类号： A61K31/4985 ,  A61K9/20 ,  A61K47/12 ,  A61K9/16

摘要： The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

公开(公告)号：US20190275102A1

公开(公告)日：2019-09-12

申请号：US16292417

申请日：2019-03-05

申请人： CADILA HEALTHCARE LIMITED

发明人： Kannan Essakimuthu MUTHAIYYAN ,  Debjani Manoj SINGH ,  Nirav Ishwarlal KHATRI ,  Omprakash Ganesh Ram SHARMA

IPC分类号： A61K38/07 ,  A61K47/32 ,  A61K47/24 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19

摘要： The present invention relates to sterile injectable compositions comprising carfilzomib and one or more phospholipids. The present invention also relates to processes for preparing the sterile injectable compositions.

公开(公告)号：US20190177309A1

公开(公告)日：2019-06-13

申请号：US16274352

申请日：2019-02-13

申请人： CADILA HEALTHCARE LIMITED

发明人： Sanjay Jagdish DESAI ,  Jayprakash Ajitsingh PARIHAR ,  Alpesh Pravinchandra SHAH

IPC分类号： C07D409/14 ,  C07D333/54 ,  C07D247/02 ,  A61K31/496 ,  C07D401/12 ,  A61K9/14

CPC分类号： C07D409/14 ,  A61K9/14 ,  A61K31/496 ,  B01D9/02 ,  C07D247/02 ,  C07D333/54 ,  C07D401/12 ,  C07D409/12 ,  C07D487/10

摘要： The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.

公开(公告)号：US20180346486A1

公开(公告)日：2018-12-06

申请号：US16002007

申请日：2018-06-07

申请人： CADILA HEALTHCARE LIMITED

发明人： Ranjit C. DESAI ,  Brijeshkumar SRIVASTAVA

IPC分类号： C07D513/04 ,  C07F3/00 ,  A61K31/40 ,  C07D209/44 ,  C07D295/096 ,  C07D491/048 ,  C07D207/06 ,  C07D209/12 ,  C07D498/04 ,  C07D495/04 ,  C07D207/20 ,  C07D207/08 ,  C07D491/04 ,  C07D487/04 ,  C07D471/04 ,  C07D217/04 ,  C07D215/20 ,  C07D215/06 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/472 ,  A61K31/47 ,  A61K31/439 ,  A61K31/437 ,  A61K31/4365 ,  A61K31/4162 ,  A61K31/407 ,  A61K31/404 ,  C07D491/08 ,  A61K31/496 ,  A61K31/4453 ,  A61K31/4375 ,  A61K31/435 ,  C07D209/08

CPC分类号： C07D513/04 ,  A61K31/40 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/435 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/472 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  C07D207/06 ,  C07D207/08 ,  C07D207/20 ,  C07D209/08 ,  C07D209/12 ,  C07D209/44 ,  C07D215/06 ,  C07D215/20 ,  C07D217/04 ,  C07D295/096 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08 ,  C07D495/04 ,  C07D498/04 ,  C07F3/00

摘要： The present invention relates to a compound (3S)-3-(4-((3-(6-Oxa-3-azabicyclo [3.1.1]heptan-3-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoic acid methods for use of this and other compounds.

公开(公告)号：US10098868B2

公开(公告)日：2018-10-16

申请号：US15475812

申请日：2017-03-31

申请人： Cadila Healthcare Limited

发明人： Jitendre D. Patel ,  Prakash Davadra ,  Snehal Patel ,  Shafiq Sheikh

IPC分类号： A61K31/40 ,  A61K9/20

摘要： The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. formula (I).

公开(公告)号：US20170166547A1

公开(公告)日：2017-06-15

申请号：US15297406

申请日：2016-10-19

申请人： CADILA HEALTHCARE LIMITED

发明人： Sanjay Jagdish DESAI ,  Jayprakash Ajitsingh PARIHAR ,  Mahesh Laljibhai RUPAPARA

IPC分类号： C07D309/10

CPC分类号： C07D309/10 ,  C07B2200/13

摘要： Dapagliflozin compounds and process for dapagliflozin preparation are described. Pharmaceutical compositions comprising dapagliflozin or solvates of dapagliflozin, for the treatment of diabetes are also described.